Applied Clinical Trials
Survey collects thoughts from industry professionals on the current and future impact of big data in clinical trials.
In October, SCORR Marketing and Applied Clinical Trials surveyed our audience on big data. As results indicate at right, most respondents agree that big data is important to the clinical research enterprise. However, when asked if it was important in their own companies, those numbers were noticeably higher in the “slightly” to “not at all” categories.
Regardless, the survey did uncover some big data trends. For example, the majority of respondents are using medical records, biomarker and registry data as sources, in that order. Of those, the medical record data is rated the most important by 48% of the respondents.
As for the future uses and impact of big data in clinical trials, some areas are brighter than others. One-third of respondents believe the EHR will be the data of record for all new patient data, and an additional one-fourth believe that predictive modeling will be used to inform preclinical and translational research.
Conversely, only 4% of respondents think patient recruitment rates will be improved in five years if they used big data. Please download the free report here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Oveporexton Shows Superior Efficacy in Phase II Narcolepsy Type 1 Trial Without Hepatotoxicity
May 16th 2025In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy frequency in patients with narcolepsy type 1, outperforming current therapies and avoiding liver toxicity seen with earlier OX2R agonists, according to results published in The New England Journal of Medicine.